罗沙司他治疗非透析CKD相关贫血的3期研究
ANDES为全球3期随机对照研究,纳入未透析的3-5期CKD贫血成人,比较罗沙司他与安慰剂。罗沙司他起始每周三次给药并按血红蛋白滴定,28-52周血红蛋白变化及24周应答率均显著优于安慰剂,纠正并维持血红蛋白且耐受性良好。
要点
- 罗沙司他可显著升高并维持非透析CKD贫血患者血红蛋白
- 24周血红蛋白应答率86.0%,明显高于安慰剂6.6%
- 不良事件与严重不良事件发生率与安慰剂相当
核心结论
- 罗沙司他可在未透析的CKD相关贫血患者中纠正并维持血红蛋白,且耐受性良好。
研究设计与样本
- 全球3期随机对照研究ANDES,纳入未透析的3-5期CKD贫血成人,罗沙司他组616例、安慰剂组306例。
- 罗沙司他初始每周三次给药,剂量滴定至血红蛋白≥11.0 g/dl后维持滴定。
主要发现
- 28-52周血红蛋白自基线平均(SD)变化:罗沙司他2.00(0.95)g/dl,安慰剂0.16(0.90)g/dl,最小二乘均值差1.85 g/dl(95%CI 1.74-1.97;P<0.0001)。
- 24周血红蛋白应答比例:罗沙司他86.0%(95%CI 83.0%-88.7%),安慰剂6.6%(95%CI 4.1%-9.9%),P<0.0001。
- 52周接受补救治疗比例:罗沙司他8.9%,安慰剂28.9%;风险比0.19(95%CI 0.14-0.28;P<0.0001)。
- 治疗中出现的不良事件与严重不良事件发生率两组相当。
关键数值与推荐
- 主要终点为28-52周血红蛋白变化及24周血红蛋白应答比例。
- 血红蛋白应答定义为血红蛋白≥11.0 g/dl且较基线升高≥1.0 g/dl(基线>8.0 g/dl),或升高≥2.0 g/dl(基线≤8.0 g/dl)。
- 剂量滴定目标为血红蛋白≥11.0 g/dl后维持滴定。
临床怎么用
- 对未透析的3-5期CKD贫血患者,可考虑口服罗沙司他并按血红蛋白≥11.0 g/dl目标滴定剂量。
- 治疗中需监测血红蛋白应答及补救治疗需求,并关注不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and tolerability of roxadustat in patients with chronic kidney disease (CKD)-related anemia not on dialysis. METHODS: ANDES was a global Phase 3 randomized study in which adults with stage 3-5 CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice weekly; dose was titrated to achieve a hemoglobin level ≥11.0 g/dl, followed by titration for maintenance. The primary endpoints were change in hemoglobin (weeks 28-52) and proportion of patients achieving a hemoglobin response (hemoglobin ≥11.0 g/dl and increase ≥1.0 g/dl [baseline >8.0 g/dl], or increase ≥2.0 g/dl [baseline ≤8.0 g/dl]) (week 24). Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were recorded. RESULTS: In roxadustat (n = 616) and placebo (n = 306) groups, hemoglobin mean (SD) change from baseline over weeks 28-52 was significantly larger for roxadustat (2.00 [0.95]) versus placebo (0.16 [0.90]), corresponding to least-squares mean difference of 1.85 g/dl (95% confidence interval [CI] 1.74-1.97; P < 0.0001). The proportion of patients achieving a response at week 24 was larger for roxadustat (86.0%; 95% CI 83.0%-88.7%) versus placebo (6.6%; 95% CI 4.1%-9.9%; P < 0.0001). The proportion of patients receiving rescue therapy at week 52 was smaller for roxadustat (8.9%) versus placebo (28.9%); hazard ratio, 0.19 (95% CI 0.14-0.28; P < .0001). The incidences of TEAEs and TESAEs were comparable. CONCLUSION: This study showed that roxadustat corrected and maintained hemoglobin and was well tolerated in patients with CKD-related anemia not on dialysis (ClinicalTrials.gov NCT01750190).
引用
- Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep. 2020. PMID: 33732977. doi:10.1016/j.ekir.2020.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。